EQT Private Equity to acquire QIAGEN with legal support from Wolf Theiss

Warsaw, 4 November 2026 – Wolf Theiss is advising EQT Private Equity on the Polish law aspects of its proposed acquisition of QIAGEN.

EQT Private Equity and QIAGEN have entered into an agreement on a recommended voluntary all-cash public takeover offer for all outstanding QIAGEN shares at a cash consideration of EUR 46.50 per share. The offer is made by a holding company indirectly controlled by the EQT XI fund, with further indirect participations held by co-investors Luxinva S.A. (a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA)) and CPP Investment Board Europe Inc. (a wholly owned subsidiary of Canada Pension Plan Investment Board (CPP Investments)). The transaction remains subject to the offer conditions and regulatory clearances and closing is expected in mid-2027.

Wolf Theiss is advising EQT Private Equity on the Polish law aspects of the transaction.

The Wolf Theiss team was led by Partners Bartosz Kuraś and Anna Dąbrowska (both Corporate/M&A), supported by Senior Associate Michał Zajączkowski (Real Estate), Counsel Agnieszka Nowak-Błaszczak and Senior Associate Anna Panek (both Employment).